SEHK:2269Life Sciences
WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds
WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune therapy.
See our latest analysis for WuXi Biologics (Cayman).
At a share price of HK$37.96, WuXi Biologics (Cayman) has seen a 26.79% 30 day share price return and a 16.66% year to date share price return. Its 1 year total shareholder return of 42.44% contrasts with weaker multi year total...